Pore-forming toxins are critical virulence factors for many bacterial pathogens and are central to Staphylococcus aureus-mediated killing of host cells. S. aureus encodes pore-forming bi-component leukotoxins that are toxic towards neutrophils, but also specifically target other immune cells. Despite decades since the first description of staphylococcal leukocidal activity, the host factors responsible for the selectivity of leukotoxins towards different immune cells remain unknown. Here we identify the human immunodeficiency virus (HIV) co-receptor CCR5 as a cellular determinant required for cytotoxic targeting of subsets of myeloid cells and T lymphocytes by the S. aureus leukotoxin ED (LukED). We further demonstrate that LukED-dependent cell killing is blocked by CCR5 receptor antagonists, including the HIV drug maraviroc. Remarkably, CCR5-deficient mice are largely resistant to lethal S. aureus infection, highlighting the importance of CCR5 targeting in S. aureus pathogenesis. Thus, depletion of CCR5 1 leukocytes by LukED suggests a new immune evasion mechanism of S. aureus that can be therapeutically targeted.
Pore-forming toxins are critical virulence factors for many bacterial pathogens and are central to Staphylococcus aureus-mediated killing of host cells. S. aureus encodes pore-forming bi-component leukotoxins that are toxic towards neutrophils, but also specifically target other immune cells. Despite decades since the first description of staphylococcal leukocidal activity, the host factors responsible for the selectivity of leukotoxins towards different immune cells remain unknown. Here we identify the human immunodeficiency virus (HIV) co-receptor CCR5 as a cellular determinant required for cytotoxic targeting of subsets of myeloid cells and T lymphocytes by the S. aureus leukotoxin ED (LukED). We further demonstrate that LukED-dependent cell killing is blocked by CCR5 receptor antagonists, including the HIV drug maraviroc. Remarkably, CCR5-deficient mice are largely resistant to lethal S. aureus infection, highlighting the importance of CCR5 targeting in S. aureus pathogenesis. Thus, depletion of CCR5 1 leukocytes by LukED suggests a new immune evasion mechanism of S. aureus that can be therapeutically targeted.
S. aureus is a bacterial pathogen that causes significant morbidity and mortality worldwide. The organism is responsible for a myriad of diseases, from skin and soft-tissue infections, to more invasive diseases including necrotizing pneumonia and sepsis. S. aureus secretes several protein products that allow the organism to subvert the host immune system. Such factors include super-antigens, antibody binding proteins, cytolytic peptides and pore-forming cytotoxins 1 .
Pore-forming toxins are secreted by a substantial number of pathogenic bacteria 2 . The toxins are secreted as water-soluble monomers that recognize host cell membranes, oligomerize, and insert a-helical or b-barrel pores into the lipid bilayer 2 . Pore formation disrupts osmotic balance and membrane potential, ultimately leading to cell death 2 . S. aureus strains that infect humans produce up to four different b-barrel, bi-component, pore-forming toxins (HlgACB, LukED, LukSF-PV/PVL and LukAB/HG) that exhibit a unique tropism for host immune cells and contribute to the greater virulence of S. aureus 1, 3, 4 . The precise repertoire of immune cells targeted by the pore-forming leukotoxins remains to be fully determined. Even now, more than a century since the first description of staphylococcal leukocidal activity 5, 6 , our understanding of leukotoxin function in vivo is limited because of an absence of known host-derived specificity determinants.
CCR5 is required for LukED cytotoxicity
To identify potential leukotoxin receptors, we purified recombinant LukED, LukAB and LukSF-PV and assessed their ability to kill a set of human cell lines 4, 7 . Granulocyte-like human cells (PMN-HL60) were killed in 1 h by LukAB and LukSF-PV, but not LukED (Fig. 1a ). In contrast, LukED was cytotoxic to a human T-cell line ectopically expressing CCR5 (HUT-R5); whereas another T-cell line (Jurkat), which lacks detectable CCR5, was insensitive ( Fig. 1a ). This suggested that CCR5 was involved in LukED cytotoxicity towards HUT-R5 cells. Accordingly, when CCR5 amounts were reduced in HUT-R5 cells using lentiviral CCR5 short hairpin RNA (shRNA), the cells were protected from LukED-mediated killing ( Fig. 1b and Supplementary Fig. 1a, b ).
Complementary to these findings, ectopic expression of CCR5 was sufficient to render Jurkat and H9 cells ( Supplementary Fig. 1c ) susceptible to LukED cytotoxicity ( Fig. 1c ). As expected, on the basis of the mode of action of the bi-component leukotoxins, CCR5dependent LukED-mediated cytotoxicity required both LukE and LukD subunits ( Supplementary Fig. 2a, b) . A human osteosarcoma cell line engineered to constitutively express CCR5 (GHOST.R5 cells) 8 was also sensitive to LukED, but not to LukAB or LukSF-PV (Fig. 1d ). The sensitivity of GHOST cells to LukED was specific to CCR5 expression, as overexpression of additional T-cell-specific chemokine receptors (CCR1, CCR2, CCR3, CXCR4, CCR8 and CXCR6) in these cells did not confer susceptibility to LukED ( Supplementary Fig. 2c ).
CCR5 antagonists block LukED cell killing
CCR5 is a co-receptor required for HIV infection [9] [10] [11] and has been targeted with small molecule antagonists aimed at restricting HIV entry into host cells 11 . We found that one such clinically approved receptor antagonist, maraviroc, potently blocked LukED killing of CCR5 1 cells ( Fig. 1e and Supplementary Fig. 3a ) at concentrations similar to those required to block HIV infection ( Supplementary Fig. 3b ). Similar inhibitory effects were observed with the CCR5 antagonists vicriviroc and TAK-779, as well as chemokines that are natural ligands of CCR5 ( Supplementary Fig. 3a , c) 12, 13 . We found that maraviroc resulted in complete blockade of LukED pore formation, an essential process for cytotoxicity ( Fig. 1f and Supplementary Fig. 3d ).
We next investigated whether S. aureus was able to kill CCR5 1 cells in a LukED-dependent manner. The expression of lukED in S. aureus is inherently low during in vitro growth 7 . However, deletion of the transcription factor Rot, a potent repressor, results in the enhanced expression and production of LukED by S. aureus 7 . Thus, to assess S. aureus cytotoxicity towards CCR5 1 cells, Jurkat or Jurkat-R5 cells were infected with S. aureus Drot (Sa LukED 1 ) and S. aureus DrotDlukED (Sa LukED 2 ) mutants. Jurkat-R5 cells were killed by S. aureus in a LukED-dependent manner, whereas Jurkats lacking CCR5 were resistant to killing ( Fig. 1g ). Additionally, Jurkat-R5 killing by S. aureus was completely blocked by maraviroc ( Fig. 1h ).
LukE interacts directly with CCR5
To characterize more precisely the LukED-CCR5 interaction on target cells, we first determined whether monoclonal antibodies specific towards extracellular regions of CCR5 (ref. 14) were sufficient to block toxin activity ( Fig. 2a ). Antibodies against extracellular loop 2 (ECL-2), but not the amino (N) terminus of the receptor or CXCR4, significantly blocked toxin killing ( Fig. 2a ) and prevented association of functional green fluorescent protein (GFP)-labelled toxin (Supplementary Fig. 4 ) with the cell surface of sorted primary human CD4 1 CCR5 1 T cells ( Fig. 2b ). Furthermore, toxin association with the cell surface of CCR5 1 cells was also reduced in the presence of CCL5, and was completely blocked upon addition of maraviroc, similar to CD4 1 CCR5 2 T cells ( Fig. 2c ). To determine whether LukED interacts with CCR5, pull-down assays were conducted with purified toxin and solubilized CCR5. We found that CCR5 interacted with LukE but not LukD (Fig. 2d ). This interaction was significantly reduced in the presence of maraviroc, natural ligands of CCR5, as well as monoclonal antibody 45531 directed against ECL-2, but not 3A9 directed against the N terminus of CCR5 ( Fig. 2e, f) . Additionally, incubation of LukE (75-fold molar excess) with CCR5 1 cells largely blunted native ligand-induced CCR5 signalling as measured by calcium mobilization ( Supplementary Fig. 5 ). LukE itself does not seem to induce CCR5 signalling ( Supplementary Fig. 6a, b ). Surface plasmon resonance studies with immobilized native CCR5 (ref. 15 ) and purified LukE or LukD subunits confirmed the pull-down studies and determined that LukE, but not LukD, binds to CCR5 in a anti-CCR5 monoclonal antibodies (35 mg ml 21 ) followed by exposure to LukED (10 mg ml 21 ). b, Membrane association of GFP-LukED (10 mg ml 21 ) to the surface of primary CD4 1 CCR5 1 T cells with or without the indicated monoclonal antibodies (25 mg ml 21 ) as determined by fluorescence-activated cell sorting (FACS). c, Membrane association of GFP-LukED (10 mg ml 21 ) on the surface of primary CD4 1 CCR5 1 T cells with or without maraviroc (MVC) (100 ng ml 21 ), CCL5 (5 mg ml 21 ) or on CD4 1 CCR5 2 T cells. 
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time-dependent and saturable manner, with an apparent dissociation constant (K d ) of 39.6 6 0.4 nM ( Fig. 2g and Supplementary Fig. 7a, b ). This interaction was specific, as evidenced by an inability of LukE to bind native CXCR4 ( Fig. 2g ).
LukED kills CCR5 1 myeloid cells and T cells
We next sought to determine the subsets of primary human lymphoid and myeloid cells targeted by LukED. Treatment of blood lymphocytes with LukED resulted in specific depletion of CCR5 1 T cells, most of which were effector memory T lymphocytes ( Fig. 3a and Supplementary Fig. 8 ). As with cell lines, the CCR5-dependent killing of primary cells was completely blocked by maraviroc ( Fig. 3a and Supplementary Fig. 8 ). A proportion of individuals of Northern European heritage harbour a 32 base-pair deletion in the CCR5 gene (D32 CCR5), resulting in a truncated protein that cannot be surface localized, thus rendering the CD4 1 T cells refractory to HIV infection 11, 16, 17 . Similarly, primary T cells expanded from a D32 CCR5 donor were also resistant to LukED cytotoxicity (Fig. 3b ). In keeping with the notion that CCR5 is required for HIV-1 entry into CD4 1 T cells [9] [10] [11] , selective depletion of CCR5 1 T cells by LukED suppressed HIV-1 spread ( Supplementary Fig. 9 ). Memory T cells can be classified into functional subsets on the basis of differential chemokine receptor profiles and cytokine production.
Among T-cell subsets, the CCR6 1 CCR5 1 subset produces more interleukin (IL)-17 and interferon (IFN)-c than CCR6 1 CCR5 2 T cells 18 . Consistent with this association, depletion of CCR5 1 CD4 1 T cells with LukED greatly reduced the proportion of IFN-c-and IL-17-producing cells compared with purified CD4 1 T-cell controls ( Fig. 3c, day 0) . Incubation with the cc-cytokines IL-7 and IL-15 significantly enhances the proportion of IL-17 1 and IL-17 1 /IFN-c 1 by CCR6 1 memory T cells 19 . We found that when human CD4 1 T cells were first treated with LukED, followed by 7 days of culture with IL-7 and IL-15, there was a substantial reduction in the induction of IFN-c and IL-17/IL-22-secreting CCR6 1 T cells (Fig. 3c ). This finding correlates well with depletion of the CCR6 1 CCR5 1 memory progenitor subset ( Supplementary Fig. 10 ). In addition to Th1 and Th17 effector cells, LukED also killed macrophages and dendritic cells in a CCR5dependent manner (Fig. 3d ).
LukED targets CCR5 1 cells in vivo
Next we examined the contribution of CCR5 to S. aureus pathogenesis and determined the influence of LukED on the targeted killing of CCR5 1 cells in vivo. We found that murine CCR5 (mCCR5) renders transfected 293T cells fully susceptible to the toxin ( Supplementary  Fig. 11a, b) . Additionally, primary murine macrophages treated with high concentrations of maraviroc were partly protected from toxinmediated killing, confirming that LukED is directly targeting mCCR5 ( Supplementary Fig. 11c ). Because maraviroc is potent towards human CCR5 but not mCCR5 ( Fig. 1e and Supplementary Fig. 11 ) 20 , we chose to study wild-type (WT) and CCR5-deficient mice with the hypothesis that the latter would be resistant to LukED cytotoxicity. S. aureuselicited lymphocytes and macrophages from WT mice were highly susceptible to purified LukED, whereas lymphocytes and macrophages isolated from CCR5 2/2 mice were markedly resistant ( Fig. 4a, b ). To validate further that S. aureus kills CCR5 1 leukocytes in vivo, we implemented a peritonitis model in which WT and CCR5 2/2 mice were infected with S. aureus. CCR5 surface expression was not required for the initial influx of immune cells to the infection site, as the cells recovered and their profiles were identical among all mice (Supplementary Fig. 12 ). However, lymphocytes and macrophages elicited in vivo in WT mice were more susceptible to S. aureus killing than those from the CCR5 2/2 mice (Fig. 4c, d) . LukED is associated with S. aureus pathogenesis in a murine model of systemic infection 7 . Using this model, CCR5 2/2 mice infected with WT S. aureus exhibited significantly reduced bacterial burden in the kidneys than those of infected WT mice (Fig. 4e ), a phenotype similar to that observed for mice infected with a S. aureus DlukED mutant 7 . After 96 h, infected CCR5 2/2 mice also exhibited significantly reduced serum pro-inflammatory cytokines and chemokines and showed a commensurate reduction in innate immune cells in the kidney compared with WT mice (Fig. 4f, g) , signs consistent with infection resolution. Additionally, when WT mice were challenged systemically with WT or a DlukED mutant, we observed LukED-dependent killing of CCR5 1 macrophages in infected kidneys, consistent with our hypothesis that LukED is capable of targeting CCR5 1 leukocytes during infection (Fig. 4h ). In support of the importance of CCR5 targeting in vivo, the mortality associated with S. aureus bloodstream infection was reduced for CCR5-deficient mice, a phenotype similar to that of mice challenged with strains of S. aureus lacking lukED (Fig. 4i ).
Discussion
To our knowledge, CCR5 is the first described cellular receptor that is necessary and sufficient for the killing of mammalian cells by a staphylococcal bi-component leukotoxin. Thus, in addition to HIV, Toxoplasma gondii and poxviruses (vaccinia and myxoma) 9,21-24 , S. aureus can also exploit CCR5 to target immune cells. Interestingly, the D32 allele of CCR5 is thought to have been acquired through selective pressure imparted by a deadly pathogen 25, 26 . Yersinia pestis or variola virus were postulated as potential driving forces behind this selection, but these hypotheses have either been discounted or remain uncertain in favour of an older selection event incited by an immunecell-targeting pathogen 24, 27 . Our findings put forth the possibility that resistance to S. aureus leukotoxins may have influenced the selection of the D32 allele. 
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The finding that LukED selectively kills CCR5 1 T cells, macrophages and dendritic cells extends the repertoire of immune cells targeted by this leukotoxin and supports a role for these leukocytes in the resolution of S. aureus infection. The lukED gene is believed to be present in many clinically relevant strains (.70%) including clones responsible for most infections in the USA and Germany, although it is absent in a subset of strains causing hospital-acquired infection (for example EMRSA15/16) in the UK [28] [29] [30] . Most isolates lacking lukED seem to be of clonal complex 30 (USA200/EMRSA16), which is known to produce low amounts of cytotoxins 31 . Conceivably, the pathogenesis of these strains is influenced by the weakened immune status of hospitalized patients rather than toxic molecules. In contrast, we predict that virulent clinical strains producing large amounts of LukED (for example, clonal complex 8) 7 use the toxin to eliminate antigen-presenting cells as well as S. aureus-specific CCR5 1 Th1/ Th17 cells, which are induced by the bacterium 32 and are protective against infection 33, 34 . In support of this hypothesis, we demonstrate that LukED kills CCR5 1 cells in vivo during systemic infection and that mice lacking CCR5 are protected from the mortality associated with acute S. aureus disease. Current systemic murine infection models are insufficient to evaluate reliably CCR5 hi T-cell susceptibility to LukED (data not shown). However, our in vitro data and in vivo studies with CCR5 1 macrophages strongly support the notion that subsets of CCR5 hi T cells are also targeted in vivo.
Interestingly, LukED-mediated toxicity towards neutrophils and monocytes is not blocked by maraviroc (data not shown), suggesting LukED targets these cells through alternative and non-redundant mechanisms. This point also implies a role for CCR5 1 myeloid cells and T cells in resolving acute infection, one that extends beyond the initial control of infection imparted by neutrophils. The finding that LukED toxicity towards CCR5 1 cells is potently neutralized by a clinically approved CCR5 antagonist (maraviroc) suggests that these types of drug could provide much-needed therapeutic alternatives in the treatment of S. aureus infections.
METHODS SUMMARY
Cell lines and primary human cells were maintained in RPMI plus 10% fetal bovine serum with penicillin and streptomycin, unless supplemented as otherwise indicated, and were incubated with LukE, LukD or LukED as previously described 7 . All blood samples were obtained from anonymous healthy donors as buffy coats (New York Blood Center). The New York Blood Center obtained written informed consent from all participants. Animal experiments were performed in accordance with the Institutional Animal Care and Use Committee at New York University School of Medicine. CCR5-overexpressing cell lines and CCR5 shRNA knockdowns were generated by lentiviral-based tranduction as previously described 35 . Isolation of human peripheral blood mononuclear cells (PBMC) and their sorted subsets was performed as previously described 19 . 
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Paradoxically, clone 2D7 also binds to ECL-2 of CCR5 similar to that of clone 45531, which blocks toxin activity. However, 2D7 and 45531 do bind to distinct portions of ECL-2 (the N-terminal portion and carboxy (C)-terminal portion, respectively) perhaps explaining this phenomenon 38 . Alternatively, our staining protocols may not have sufficiently saturated all receptor sites, thereby allowing functional characterization of toxin in the presence of 2D7. Experiments assessing maraviroc, natural ligand or antibody inhibition of LukED membrane association were conducted in a similar fashion. However, in these instances cells were first pre-incubated for 30 min with maraviroc (100 ng ml 21 ), CCL5 (5 mg ml 21 ), 3A9, 45531 or CXCR4 monoclonal antibodies (25 mg ml 21 ) or buffer before addition of a lethal concentration of LukE-GFP 1 LukD to the cells (5-10 mg ml 21 ). After treatment, cells were washed, re-suspended in fixation buffer (FACS buffer 1 2% paraformaldehyde) for 15 min at room temperature, washed again, re-suspended in FACS buffer, and the fluorescence of bound toxin was monitored by flow cytometry. Cells are shown as the percentage that were GFP positive. Surface plasmon resonance analysis of LukE and LukD binding to solubilized CCR5 and CXCR4. Binding kinetics of LukE and LukD to CCR5 and CXCR4 by surface plasmon resonance were measured as previously described 15, [39] [40] [41] [42] . This approach has also been used to detect ligand interactions with CXCR1 and CXCR2 (refs 43, 44) . A C9-tagged CCR5 was solubilized using 50 mM HEPES, pH 7.0, 150 mM NaCl, 0.1% DDM, 0.1% CHAPS, 0.02% CHS 15 . This solubilization scheme is known to retain conformationally specific antibody binding to both CCR5 and CXCR4 (ref. 15 ). Approximately 700 relative units (RU) of the CCR5 receptor was captured onto a 1D4 antibody-bound CM5 chip 15, 40, 41 . Cells expressing a C9-tagged CXCR4 receptor were also solubilized as a control surface in the same buffer 41 . C9-CXCR4 was captured to approximately 1,200 RU. LukE or LukD was diluted to 1.7 mM in running buffer containing 50 mM HEPES, pH 7.0, 150 mM NaCl, 0.02% CHS, 0.1% DDM and 0.1% Chaps and tested for binding in a threefold dilution series at a flow rate of 50 ml min 21 . Each concentration series was replicated twice as shown by the overlaid sensorgrams. All data were collected at 25 uC and conducted at least twice in duplicate. Biochemical studies to detect interactions between LukED and CCR5. 293T cells were transfected with a vector containing HA-tagged CCR5 (Missouri S&T cDNA Resource Center; www.cdna.org), followed by solubilization (approximately 2.0 3 10 7 cells per condition) in PBS 1 1% Brij010 1 Complete EDTAfree protease inhibitor cocktail (Roche). Solubilized CCR5 was then added to 25 ml of nickel resin containing no toxin or bound LukE, LukD or LukED. For the maraviroc, natural ligand and antibody inhibition experiments, the solubilized CCR5 was pre-incubated for 30 min at room temperature with 5 mg ml 21 of maraviroc, 10 mg ml 21 of each chemokine or 35 mg ml 21 of each antibody followed by incubation with nickel resin containing LukE. After incubation with cell lysates, the resin/protein complexes were fixed with 2 mM DTSSP (Pierce) for 30 min, quenched with 20 mM Tris pH 8.0 for 15 min, washed four times in PBS 1 1% Brij010 and boiled in 43 SDS boiling buffer. All samples were run on a 10% SDS-PAGE gel at 80 V, followed by transfer to nitrocellulose at 1 A for 1 h. Membranes were blocked in PBS 1 0.01% Tween 1 5% milk for 1 h and incubated overnight with either a-HA antibody for CCR5 (Covance) or a-His antibody (Cell Sciences) for LukE and LukD. The following day, secondary goat a-mouse-HRP antibody (Bio-Rad) was added to the membranes for 1 h followed by the addition of SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) for detection. Measurement of CCR5 activation by calcium mobilization. CCR5 activation by calcium mobilization in cell lines and primary cells was assessed using the commercial dye Fluo4-AM (Invitrogen). Cells were labelled for 30 min at room temperature with 3 mM Fluo4 in Hanks' balanced salt solution, followed by three washes in Hanks' balanced salt solution and incubation at 37 uC for 30 min. Cells were analysed on a flow cytometer over time and, at 100 s, ligand (CCL3, CCL4, CCL5, 10 ng ml 21 ) or LukE (10-20 mg ml 21 ) was added to the cells. Fluorescence was monitored thereafter by flow cytometry (500 events were collected per second) until the indicated completion of each experiment. For conditions in which inhibition of receptor activation was monitored, cells were pre-incubated with either maraviroc (1 mg ml 21 ) or LukE (10-20 mg ml 21 ) during the 30 min incubation at 37 uC described above. Graphs show the mean fluorescence of all events collected in 5 s intervals. Murine in vitro and in vivo experiments. In vitro assessment of peritonealelicited immune cell killing by LukED was conducted as follows. Female agematched (4-6 weeks) C57BL/6 WT or CCR5 2/2 mice (Taconic) were injected with 1 3 10 7 CFU of heat-killed S. aureus Newman DlukED intraperitoneally. Twenty-four hours later, mice were injected with an additional 1 3 10 7 CFU of the same strain. After another 24 h, mice were killed and peritoneal-elicited immune cells were lavaged with 7 ml of PBS followed by lysis of red blood cells in ACK lysing buffer and re-suspension in RPMI 1 10% FBS. LukED was then added to cells as described above and incubated for 1 h at 37 uC with 5% CO 2 . After incubation, cells were washed in PBS and stained with viability dye followed by surface staining for B220, CD11b, F480, Ly6G, CD3 and CCR5. The percentages of dead cells shown are an average of cells isolated and intoxicated from three independent mice. Means and standard deviations are shown.
For experiments designed to measure S. aureus killing of CCR5 1 cells in vivo, female age-matched (4-6 weeks) C57BL/6 WT or CCR5 2/2 mice (Taconic) were injected on day 1 with 1 3 10 7 heat-killed S. aureus to promote the recruitment of CCR5 1 macrophages and lymphocytes to the peritoneum. On day 2, mice were challenged with live S. aureus Drot followed by the isolation of peritoneal immune cells 16-20 h later. Isolated cells were processed for FACS as described above and the viability of lymphocytes and macrophages was evaluated. The percentages of dead lymphocytes were averaged from 10 WT and 10 CCR5 2/2 animals; representative FACS plots are shown.
For murine systemic infections, female age-matched (4-6 weeks) C57BL/6 WT or CCR5 2/2 mice (Taconic) were infected with WT S. aureus Newman as previously described 7 . After 96 h, serum was collected and kidneys removed, homogenized, processed for FACS and plated as previously described 7 . All survival curves were conducted as previously described using WT S. aureus Newman and an isogenic DlukED mutant 7 . For flow cytometry of immune cells from WT or DlukED infected kidneys, organs were removed after 96 h and mechanically homogenized. Immune cells in homogenized tissues were enriched by performing a 40/80 Percoll (GE Healthcare) density gradient centrifugation. Cells were subsequently processed for surface and viability staining thereafter (see above).
